Produced in Unit 2 of Rafarma’s Terbuni plant, Ceftriaxone formulated for injections will be packed in 10ml bottles with single gram dosages.
With an estimated Ceftriaxone market of more than $51m per year in Russia, as per 2011 official statistics, Rafarma intends to take 50% of the market in the country for the antibiotic.
ZAO "SIA International" and the Russian national retail chain OAO "A5 Pharmacy Ltd." have signed a long-term national and regional distribution contracts with Rafarma.
Rafarma CEO David Anderson said with 17 national distributors signing long-term agreements, the company’s production and penetration of market share remains assured.
"These contracts were an integral part of Rafarma’s expansion plan and will play a vital role in the expansion of operations. Rafarma has positioned itself to become one of the five leading pharmaceutical companies in the Russian Federation," Anderson added.